A paradigm shift in noninvasive prenatal screening has been made with the discovery of cell-
free fetal DNA in maternal plasma. Noninvasive prenatal screening is primarily used to …

Purpose Noninvasive prenatal screening (NIPS) using cell-free DNA has been assimilated
into prenatal care. Prior studies examined clinical validity and technical performance in high …

Purpose This workgroup aimed to develop an evidence-based clinical practice guideline for
the use of noninvasive prenatal screening (NIPS) for pregnant individuals at general risk for …

Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

Valid data on prenatal cell-free DNA-based screening tests for copy number variations and
microdeletions are still insufficient. We aimed to compare different methodological …

Cell‐free fetal DNA analysis has an established role in prenatal assessments. It serves as a
source of fetal genetic material that is accessible non‐invasively from maternal blood …

Objective To assess the detection efficiency of noninvasive prenatal testing (NIPT) for fetal
autosomal aneuploidy, sex chromosome aneuploidy (SCA), other chromosome aneuploidy …

Abstract Objective 22q11. 2 deletion syndrome (DS) is a serious condition with a range of
features. The small microdeletion causing 22q11. 2DS makes it technically challenging to …

Objective: To assess the association between lipid metabolism and fetal fraction, which is a
critical factor in ensuring a highly accurate non-invasive prenatal testing (NIPT), and on the …

Objective We and others have previously demonstrated that the size-selection enrichment
method could remarkably improve fetal fraction (FF) in the early gestational age (GA, 12–13 …